Rabies immune globulin - Kamada

Drug Profile

Rabies immune globulin - Kamada

Alternative Names: Anti-rabies IgG - Kamada; HRIG - Kamada; Human rabies immunoglobulin - Kamada; KamRAB; KEDRAB

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Kamada; Kedrion; OncBioMune
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Rabies

Most Recent Events

  • 25 Aug 2017 Registered for Rabies (Prevention) in USA (IM)
  • 25 Aug 2017 Kedrion expects to launch rabies immune globulin in USA in early 2018
  • 10 Mar 2017 Vitel Laboratorios has been acquired by OncBioMune Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top